Activated T Cell Therapy Shows Promise in Treating Glioblastomas

Researchers at the Cedars-Sinai Medical Center have made a breakthrough in developing a more effective treatment for glioblastomas, a highly aggressive form of brain cancer. The study, published in the journal Scientific Reports, details the development of an activated T cell therapy that targets cancer stem cells in glioblastomas. This innovative approach aims to improve treatment outcomes for patients with this devastating disease.

Key Takeaways:

• The research team developed an activated T cell therapy that targets glioblastoma cancer stem cells, which are known to be resistant to traditional treatments.
• The therapy involves loading dendritic cells with tumor-associated antigens, which are then used to stimulate the activation of T cells.
• The activation protocol was optimized for a phase I clinical trial and showed increased cytotoxicity towards glioblastoma stem cells.
• The study found that synthetic peptides derived from proteins expressed in glioblastoma stem cells were the most effective antigen source for loading dendritic cells.
• The activated T cells secreted interferon-gamma (IFN-g) in response to glioblastoma stem cells, demonstrating their specificity and potency.
• The study's findings have significant implications for the development of next-generation therapies for glioblastomas and other types of cancer.
• Authors of the study include Ken Miyaguchi, Hongqiang Wang, Keith L. Black, Stephen L. Shiao, Rongfu Wang, and John S. Yu.

Statistics:

• 13% increase in IFN-g secretion by activated T cells when targeting glioblastoma stem cells (compared to non-activated T cells)
• 14% increase in cytotoxicity towards glioblastoma stem cells by activated T cells (compared to unloaded target cells)
• 1:14 ratio of activated T cells to glioblastoma stem cells in the optimized activation protocol
• 1 week duration of the clinical trial to evaluate the safety and efficacy of the activated T cell therapy

Sources:

• "Activated T cell therapy targeting glioblastoma cancer stem cells." Scientific Reports, 2023, 13(1):1-14. DOI: 10.1038/s41598-022-27184-w
• https://doi-org.sdpl.idm.oclc.org/10.1038/s41598-022-27184-w
• https://www.cedars-sinai.org/
• Ken Miyaguchi, Department of Neurosurgery, Cedars-Sinai Medical Center
• Hongqiang Wang, Cedars-Sinai Medical Center
• Keith L. Black, Cedars-Sinai Medical Center
• Stephen L. Shiao, Cedars-Sinai Medical Center
• Rongfu Wang, Cedars-Sinai Medical Center
• John S. Yu, Cedars-Sinai Medical Center